Bone morphogenetic protein 9 regulates tumor growth of osteosarcoma cells through the Wnt/β-catenin pathway

Lv,Zilan; Wang,Chuan; Yuan,Taixian; Liu,Yuehong; Song,Tao; Liu,Yueliang; Chen,Chu; Yang,Min; Tang,Zuchuan; Shi,Qiong; Weng,Yaguang

doi:10.3892/or.2013.2931

Bone morphogenetic protein 9 regulates tumor growth of osteosarcoma cells through the Wnt/β-catenin pathway

Authors:
- Zilan Lv
- Chuan Wang
- Taixian Yuan
- Yuehong Liu
- Tao Song
- Yueliang Liu
- Chu Chen
- Min Yang
- Zuchuan Tang
- Qiong Shi
- Yaguang Weng
View Affiliations

Affiliations: Key Laboratory of Diagnostic Medicine Designated by the Chinese Ministry of Education, Chongqing Medical University, Chongqing 400016, P.R. China, Department of Gastroenterology, The Third People's Hospital of Chongqing, Chongqing 400014, P.R. China, Department of Clinical Laboratory, The Fourth Hospital of Xi'an, Xi'an, Shaanxi 710004, P.R. China
Published online on: December 16, 2013 https://doi.org/10.3892/or.2013.2931
Pages: 989-994

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Bone morphogenetic protein 9 (BMP9) is a member of the transforming growth factor-β (TGF-β) family, which has been shown to regulate the progression of several tumors. Recent studies indicated that BMP9 affects osteosarcoma (OS) processes, but its specific roles and molecular mechanisms have yet to be fully elucidated. The human OS cell lines 143B and MG63 were used for the present study. We found that BMP9 overexpression suppressed the growth of OS cells, whereas inhibition of BMP9 reversed this effect. Our results also showed that BMP9 overexpression induced G0/G1 phase arrest and apoptosis in OS cells. We further investigated the possible molecular mechanisms mediating the biological role of BMP9. We observed that BMP9 overexpression reduced β-catenin mRNA and protein levels, and also downregulated its downstream proteins c-Myc and osteoprotegerin (OPG) and inhibited the phosphorylation levels of GSK-3β (Ser 9) in OS cells, whereas inhibition of BMP9 reversed these effects. Moreover, the suppressive effects of BMP9 overexpression on OS cells was reversed by exogenous β-catenin expression, but augmented by β-catenin silencing. In conclusion, our results revealed that BMP9 can regulate tumor growth of OS cells through the Wnt/β-catenin pathway. Therefore, BMP9 may be a new therapeutic target in OS.

View Figures

View References

1	Young JL Jr and Miller RW: Incidence of malignant tumors in U.S. children. J Pediatr. 86:254–258. 1975. View Article : Google Scholar : PubMed/NCBI
2	Fagioli F, Biasin E, Mereuta OM, et al: Poor prognosis osteosarcoma: new therapeutic approach. Bone Marrow Transpl. 41:S131–S134. 2008. View Article : Google Scholar : PubMed/NCBI
3	Barker N: The canonical Wnt/beta-catenin signalling pathway. Methods Mol Biol. 468:5–15. 2008. View Article : Google Scholar : PubMed/NCBI
4	Clevers H: Wnt/beta-catenin signaling in development and disease. Cell. 127:469–480. 2006. View Article : Google Scholar : PubMed/NCBI
5	Behrens J: Control of beta-catenin signaling in tumor development. Ann NY Acad Sci. 910:21–35. 2000. View Article : Google Scholar : PubMed/NCBI
6	Haydon RC, Deyrup A, Ishikawa A, et al: Cytoplasmic and/or nuclear accumulations of the beta-catenin protein is a frequent event in human osteosarcoma. Int J Cancer. 102:338–342. 2002. View Article : Google Scholar : PubMed/NCBI
7	Iwaya K, Ogawa H, Kuroda M, Izumi M, Ishida T and Mukai K: Cytoplasmic and/or nuclear staining of beta-catenin is associated with lung metastasis. Clin Exp Metastasis. 20:525–529. 2003. View Article : Google Scholar : PubMed/NCBI
8	MacDonald BT, Tamai K and He X: Wnt/beta-catenin signaling: components, mechanisms, and diseases. Dev Cell. 17:9–26. 2009. View Article : Google Scholar : PubMed/NCBI
9	McQueen P, Ghaffar S, Guo Y, Rubin EM, Zi X and Hoang BH: The Wnt signaling pathway: implications for therapy in osteosarcoma. Expert Rev Anticancer Ther. 11:1223–1232. 2011. View Article : Google Scholar : PubMed/NCBI
10	Sato MM, Nakashima A, Nashimoto M, Yawaka Y and Tamura M: Bone morphogenetic protein-2 enhances Wnt/beta-catenin signaling-induced osteoprotegerin expression. Genes Cells. 14:141–153. 2009. View Article : Google Scholar : PubMed/NCBI
11	Singh A and Morris RJ: The Yin and Yang of bone morphogenetic proteins in cancer. Cytokine Growth Factor Rev. 21:299–313. 2010. View Article : Google Scholar : PubMed/NCBI
12	Kim M and Choe S: BMPs and their clinical potentials. BMB Rep. 44:619–634. 2011. View Article : Google Scholar
13	Herrera B, van Dinther M, ten Dijke P and Inman GJ: Autocrine bone morphogenetic protein-9 signals through activin receptor-like kinase-2/Smad1/Smad4 to promote ovarian cancer cell proliferation. Cancer Res. 69:9254–9262. 2009. View Article : Google Scholar : PubMed/NCBI
14	Herrera B, García-Álvaro M, Cruz S, et al: BMP9 is a proliferative and survival factor for human hepatocellular carcinoma cells. PloS One. 8:e695352013. View Article : Google Scholar : PubMed/NCBI
15	Ye L, Kynaston H and Jiang WG: Bone morphogenetic protein-9 induces apoptosis in prostate cancer cells, the role of prostate apoptosis response-4. Mol Cancer Res. 6:1594–1606. 2008. View Article : Google Scholar : PubMed/NCBI
16	Wang K, Feng H, Ren W, et al: BMP9 inhibits the proliferation and invasiveness of breast cancer cells MDA-MB-231. J Cancer Res Clin. 137:1687–1696. 2011. View Article : Google Scholar : PubMed/NCBI
17	Liu Y, Wang W, Xu J, et al: Dihydroartemisinin inhibits tumor growth of human osteosarcoma cells by suppressing Wnt/β-catenin signaling. Oncol Rep. 30:1723–1730. 2013.PubMed/NCBI
18	Chen D, Zhao M and Mundy GR: Bone morphogenetic proteins. Growth Factors. 22:233–241. 2004. View Article : Google Scholar
19	Grcevic D, Kusec R, Kovacic N, et al: Bone morphogenetic proteins and receptors are over-expressed in bone-marrow cells of multiple myeloma patients and support myeloma cells by inducing ID genes. Leukemia Res. 34:742–751. 2010. View Article : Google Scholar : PubMed/NCBI
20	Wang L, Park P, Zhang H, et al: BMP-2 inhibits the tumorigenicity of cancer stem cells in human osteosarcoma OS99-1 cell line. Cancer Biol Ther. 11:457–463. 2011. View Article : Google Scholar : PubMed/NCBI
21	Kang Q, Sun MH, Cheng H, et al: Characterization of the distinct orthotopic bone-forming activity of 14 BMPs using recombinant adenovirus-mediated gene delivery. Gene Ther. 11:1312–1320. 2004. View Article : Google Scholar : PubMed/NCBI
22	Lv Z, Yang D, Li J, et al: Bone morphogenetic protein 9 overexpression reduces osteosarcoma cell migration and invasion. Mol Cells. 36:119–126. 2013. View Article : Google Scholar : PubMed/NCBI
23	Luo J, Chen J, Deng Z-L, et al: Wnt signaling and human diseases: what are the therapeutic implications? Lab Invest. 87:97–103. 2007. View Article : Google Scholar : PubMed/NCBI
24	Flores RJ, Li Y, Yu A, et al: A systems biology approach reveals common metastatic pathways in osteosarcoma. BMC Syst Biol. 6:502012. View Article : Google Scholar : PubMed/NCBI
25	Freeman TJ, Smith JJ, Chen X, et al: Smad4-mediated signaling inhibits intestinal neoplasia by inhibiting expression of β-catenin. Gastroenterology. 142:562–571. 2012.PubMed/NCBI
26	Neville-Webbe HL, Cross NA, Eaton CL, et al: Osteoprotegerin (OPG) produced by bone marrow stromal cells protects breast cancer cells from TRAIL-induced apoptosis. Breast Cancer Res Treat. 86:269–279. 2004.PubMed/NCBI
27	Nyambo R, Cross N, Lippitt J, et al: Human bone marrow stromal cells protect prostate cancer cells from TRAIL-induced apoptosis. J Bone Miner Res. 19:1712–1721. 2004. View Article : Google Scholar : PubMed/NCBI
28	Shipman CM and Croucher PI: Osteoprotegerin is a soluble decoy receptor for tumor necrosis factor-related apoptosis-inducing ligand/Apo2 ligand and can function as a paracrine survival factor for human myeloma cells. Cancer Res. 63:912–916. 2003.
29	Holen I, Cross SS, Neville-Webbe HL, et al: Osteoprotegerin (OPG) expression by breast cancer cells in vitro and breast tumours in vivo - a role in tumour cell survival? Breast Cancer Res Treat. 92:207–215. 2005. View Article : Google Scholar : PubMed/NCBI
30	Fodde R and Brabletz T: Wnt/beta-catenin signaling in cancer stemness and malignant behavior. Curr Opin Cell Biol. 19:150–158. 2007. View Article : Google Scholar : PubMed/NCBI
31	Forde JE and Dale TC: Glycogen synthase kinase 3: A key regulator of cellular fate. Cell Mol Life Sci. 64:1930–1944. 2007. View Article : Google Scholar : PubMed/NCBI
32	Li J, Xing M, Zhu M, et al: Glycogen synthase kinase 3 beta induces apoptosis in cancer cells through increase of survivin nuclear localization. Cancer Lett. 272:91–101. 2008. View Article : Google Scholar : PubMed/NCBI